Moreover, RET inhibition by sorafenib is not affected by the RET-V804M gatekeeper mutation, suggesting that sorafenib may yield clinical benefit in MTC patients bearing RET-V804 mutation (231). Here, RET is linked to medullary thyroid gland carcinoma.